Do NAD+ boosters like NR and NMN slow aging? Decoding the claim

NAD+ boosters, sold as nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN), are among the most aggressively marketed products in the longevity supplement category, promoted on the claim that they slow aging and extend healthspan. The premise traces back to rodent and cell studies showing that raising NAD+, a coenzyme involved in energy metabolism and DNA repair that these compounds are precursors to, can extend lifespan and improve markers of health in mice. Mouse-level lifespan data is a reasonable starting point for a hypothesis. It is not evidence of a human benefit, and the question this page checks is narrower and more specific than the marketing: what have NR and NMN actually been shown to do in human clinical trials.

What the best-designed human trial actually measured

Martens and colleagues (Nature Communications, 2018) ran the most methodologically rigorous human trial to date: a randomized, double-blind, placebo-controlled crossover study in 24 healthy middle-aged and older adults (ages 55 to 79), each completing a six-week course of NR at 500 mg twice daily and a six-week placebo phase. NAD+ metabolites rose substantially, blood NAD+ increased roughly 60% on NR compared with placebo, confirming that the supplement does what its name promises at the biomarker level. But the trial then measured essentially everything else that mattered clinically, and almost none of it moved. Systolic and diastolic blood pressure showed only a nonsignificant trend toward reduction overall (a secondary subgroup with elevated baseline pressure did show roughly a 9 mmHg drop, but this was not the trial’s primary, confirmed result). Aortic stiffness, carotid artery compliance, and flow-mediated dilation showed no meaningful change. Resting metabolic rate, glucose regulation, insulin sensitivity, and body composition were unchanged. VO2 max, treadmill endurance, and other motor function measures showed no effect. This is the honesty-defining result in the NAD+ literature: the biomarker the supplement is named for rises reliably, and nearly everything a person would actually care about did not.

The one positive human signal, and how narrow it is

The claim’s strongest human data point is Yoshino and colleagues (Science, 2021), a randomized, placebo-controlled, double-blind trial of NMN at 250 mg per day for 10 weeks in 25 postmenopausal women with prediabetes who were overweight or obese. Using a hyperinsulinemic-euglycemic clamp, the gold-standard measure of insulin sensitivity, the trial found that insulin-stimulated glucose disposal and skeletal muscle insulin signaling increased with NMN and did not change with placebo. This is a genuine, randomized, positive finding, and it deserves to be represented honestly as such. It is also narrow in every direction that matters: 25 participants, one specific population (postmenopausal, prediabetic, overweight or obese women), 10 weeks of follow-up, and an outcome, muscle insulin sensitivity on a metabolic clamp, that is a mechanistic and metabolic measure, not a hard clinical endpoint like a diabetes diagnosis, a cardiovascular event, or a measure of physical function or survival. A single small trial with a surrogate outcome in a narrow population is evidence worth tracking, not evidence that NMN slows aging.

What the pooled evidence shows on an outcome that actually matters for aging

Muscle mass and physical function are among the outcomes most directly relevant to healthy aging, and this is where the totality of human trial evidence becomes most informative. Prokopidis and colleagues (Journal of Cachexia, Sarcopenia and Muscle, 2025) pooled 10 randomized controlled trials of NMN or NR, covering participants with average ages of 61 to 83, doses from 250 to 2,000 mg per day, and durations of 3 to 24 weeks. Across every primary outcome, skeletal muscle index, handgrip strength, gait speed, and the five-time chair stand test, the pooled result was not statistically significant. The authors’ own conclusion was direct: “current evidence does not support NMN and NR supplementation for preserving muscle mass and function.” This is the closest thing the field has to a definitive answer on an aging-relevant functional outcome, and it is a null result.

The premise itself is now in question

The entire rationale for taking an NAD+ precursor rests on the idea that NAD+ declines with age and that restoring it should help. A 2026 study in Nature Metabolism (Trętowicz and colleagues) tested that premise directly, measuring whole-blood NAD+ with a rigorously validated mass spectrometry method across seven independent human cohorts. The finding: whole-blood NAD+ levels did not reliably vary with age or with lifestyle interventions such as exercise or a higher-protein diet. The only intervention in the study that reliably raised blood NAD+ was NR supplementation itself. A biomarker that does not clearly decline with age in the first place is a weaker foundation for an anti-aging product than the marketing implies, and this finding, published in one of the field’s top journals, has not been contradicted by an equally rigorous counter-study.

Where the regulatory back-and-forth fits, and where it does not

NMN’s legal status in the United States has been unsettled for years and is worth noting only because it is easy to confuse with a verdict on efficacy, which it is not. The FDA excluded NMN from the legal definition of a dietary supplement in November 2022, citing the drug preclusion clause because NMN had been authorized for investigation as a new drug. After an industry citizen petition and litigation, the FDA reversed that position in September 2025, concluding NMN had been marketed as a supplement before the drug investigation began, and formally reinstated its New Dietary Ingredient status in December 2025. Whether NMN can legally be sold as a supplement is a question about marketing law and the sequence of regulatory filings. It has no bearing on whether NMN or NR does anything measurable for human aging, which is the separate question this page is answering.

The honest bottom line

NAD+ boosters reliably do one thing in humans: they raise NAD+ levels, a biomarker. That biomarker does not clearly fall with age to begin with, undercutting the premise for correcting it. The single trial closest to testing a real aging-relevant outcome, muscle mass and physical function, pooled across 10 randomized controlled trials, found no significant benefit. The one genuinely positive human signal is a small, short, narrowly populated trial measuring a metabolic surrogate, not a health outcome. No human trial has tested NR or NMN against a hard outcome that would define “slowing aging,” survival, disease incidence, frailty, or cognitive decline among them. On the specific claim that these supplements slow aging or extend healthspan, the human evidence is not mixed or preliminary in a promising direction; it is simply not there. That gap between mechanism, biomarker movement, and mouse data on one side, and demonstrated human health benefit on the other, is exactly why this claim is not supported.